Overexpressed TIM-3 reduces the antitumor immunity of NK cells and blockade of TIM-3 may be a novel strategy to increase NK function in cancer patients (Ju et al., 2010; Sanchez-Correa et al., 2019). This evidence concerns the gene HAVCR2 and cancer.